A research team led by Hong Kong, S.A.R., China Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus.
Making use of the proprietary invention, the team has established Mat-A-Cell Limited with the aim of providing an advanced device to research institutions and companies that develop cell therapy.